Table 2. Association between the FOXO3A rs12212067 genotype and CD disease characteristics based on the Montreal classification [27].
| FOXO3A | (1) | (2) | (1) vs. (2) | (1) vs. (2) | (1) vs. (2) |
| rs12212067 | TT | TG/GG | p-value | OR | 95% CI |
| genotype status | n = 414 | n = 136 | |||
| Male sex (n = 550) | 192 (46.4%) | 75 (55.1%) | 0.076 | 0.70 | 0.48–1.04 |
| Age at diagnosis (yrs, n = 535, based on median OR+CI for > median) | |||||
| Mean ± SD | 27.7±12.3 | 25.5±10.0 | 0.437 | 1.17 | 0.79–1.73 |
| Range | (2–70) | (4–57) | |||
| Disease duration (yrs, n = 502, based on median OR+CI for > median) | |||||
| Mean ± SD | 14.5±9.2 | 15.4±9.5 | 0.235 | 0.78 | 0.52–1.17 |
| Range | (0–46) | (0–40) | |||
| Body mass index (n = 442, based on median OR+CI for > median) | |||||
| Mean ± SD | 23.2±4.0 | 22.7±4.1 | 0.223 | 1.31 | 0.85–2.03 |
| Range | (13.1–36.6) | (15.7–40.8) | |||
| Age at diagnosis | (n = 403) | (n = 132) | |||
| ≤16 years (A1) | 58 (14.4%) | 19 (10%) | 1 | 0.99 | 0.57–1.75 |
| 17–40 years (A2) | 287 (71.2%) | 101 (76%) | 0.237 | 0.76 | 0.48–1.20 |
| >40 years (A3) | 58 (14.4%) | 12 (14%) | 0.120 | 1.68 | 0.87–3.24 |
| Location (n = 535) | |||||
| (n = 401) | (n = 134) | ||||
| Terminal ileum (L1) | 58 (14.5%) | 1 (15.7%) | 0.733 | 0.91 | 0.53–1.57 |
| Colon (L2) | 48 (12.0%) | 17 (12.7%) | 0.826 | 0.94 | 0.52–1.70 |
| Ileocolon (L3) | 289 (72.0%) | 96 (71.6%) | 0.924 | 1.02 | 0.66–1.58 |
| Upper GI (L4) | 6 (1.5%) | 0 (0%) | 0.676 | 1.12 | 0.65–1.93 |
| Any ileal involvement | 347 (86.5%) | 117 (87.3%) | 0.818 | 0.93 | 0.52–1.67 |
| (L1+L3) | |||||
| Behaviour 1 (n = 521) | |||||
| (n = 391) | (n = 130) | ||||
| Non-stricturing, Non-penetrat. (B1) | 93 (23.8%) | 41 (31.5%) | 0.252 | 0.78 | 0.50–1.12 |
| Stricturing (B2) | 100 (25.6%) | 29 (22.3%) | 0.346 | 1.24 | 0.79–1.96 |
| Penetrating (B3) | 198 (50.6%) | 60 (46.2%) | 0.856 | 1.04 | 0.70–1.55 |
| Use of immunosuppressive agents 2 (n = 530) | |||||
| (n = 396) | (n = 134) | ||||
| 317 (80.0%) | 108 (80.6%) | 0.890 | 0.97 | 0.59–1.58 | |
| Surgery because of CD 3 (n = 507) | |||||
| (n = 380) | (n = 127) | ||||
| 221 (58.2%) | 76 (59.8%) | 0.739 | 0.93 | 0.62–1.40 | |
| Fistulas (n = 516) | |||||
| (n = 387) | (n = 129) | ||||
| 198 (51.2%) | 59 (45.7%) | 0.286 | 1.24 | 0.83–1.85 | |
| Perianal fistulas (n = 513) | |||||
| 45/387 (11.6%) | 13/129 (10.1%) | 0.611 | 1.184 | 0.62–2.27 | |
| Stenoses (n = 518) | |||||
| (n = 390) | (n = 128) | ||||
| 249 (63.9%) | 77 (60.2%) | 0.519 | 1.14 | 0.76–1.72 | |
For each variable, the number of patients included is given.
1
Disease behaviour was defined according to the Montreal classification. A stricturing disease phenotype was defined as presence of a stenosis without penetrating disease. The diagnosis of stenoses was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2
Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.
3
Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, and ileostomy) was included.